Agomab Spotlights Novel Lung Drug Amid Post-IPO Investor Push

ANTWERP, Belgium – May 14, 2026 – Fresh off a successful Nasdaq debut earlier this year, clinical-stage biopharmaceutical company Agomab Therapeutics is embarking on a packed schedule of scientific and investor conferences, placing its promising lung disease candidate, AGMB-447, squarely in the spotlight. The company's management will be presenting across North America and Europe, with a pivotal data reveal for its Idiopathic Pulmonary Fibrosis (IPF) treatment set for the ATS International Conference in Orlando.

This strategic tour is a critical move for the newly public company as it seeks to translate scientific promise into market confidence. Agomab aims to showcase not only its lead assets but also its unique drug development philosophy, which focuses on delivering potent therapies directly to affected organs while minimizing debilitating side effects.

A New Front in the War on Lung Fibrosis

The centerpiece of Agomab's upcoming presentations is the data for AGMB-447, an inhaled, lung-restricted inhibitor designed to combat Idiopathic Pulmonary Fibrosis. IPF is a devastating and progressive disease that causes irreversible scarring of the lungs, leading to a grim prognosis and a significant unmet medical need. Current treatments, such as pirfenidone and nintedanib, can slow the disease's progression but are not curative and come with their own set of side effects.

Agomab's approach with AGMB-447 is to directly target a core driver of fibrosis—the TGFβ pathway—but in a highly localized manner. The transforming growth factor-beta (TGFβ) pathway is a well-known culprit in the development of fibrosis, but systemically blocking it has proven difficult due to its essential roles in healthy bodily functions. By developing an inhaled small molecule that inhibits a key receptor in this pathway, ALK5, Agomab believes it can deliver a high therapeutic dose directly to the lungs while avoiding the systemic toxicities that have plagued previous efforts.

The poster presentation at the ATS conference, titled ‘AGMB-447...Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects,’ is expected to provide the first detailed public look at this strategy's success. The company has already reported that an initial Phase 1 study in 108 healthy volunteers found AGMB-447 to be generally safe and well-tolerated, with evidence of target engagement in the lungs and low systemic exposure. The company is now advancing the final part of that study in IPF patients and plans to initiate a larger Phase 2 trial in the second half of 2026.

From IPO to Investor Roadshow

While the scientific community's attention will be on the ATS conference, Agomab's management has an equally important audience in its sights: the investment community. The company's six-conference tour includes fireside chats and one-on-one meetings at high-profile events like the H.C. Wainwright BioConnect Conference, the RBC Capital Markets Global Healthcare Conference, and the Leerink Partners Therapeutics Forum.

This intensive investor outreach follows Agomab's successful Initial Public Offering in February 2026, which raised approximately $200 million. The IPO provided the Belgian biotech with a substantial cash runway, which it estimates will fund operations into the first half of 2029. With a market capitalization hovering around $600 million, the company is now tasked with justifying its valuation and building a compelling growth narrative.

Analysts have so far been optimistic. The consensus rating among those covering the stock is a "Buy," with an average 12-month price target of $32.00, suggesting significant upside from its recent trading price of around $11. This roadshow is a crucial opportunity for Agomab to reinforce that positive sentiment, clearly articulate its clinical and commercial strategy, and attract the long-term institutional investors necessary to fund its ambitious pipeline through to potential approval.

A Pipeline Built on Precision

Beyond its IPF candidate, Agomab is advancing a pipeline built on its core philosophy of organ-restricted therapy for fibro-inflammatory diseases. The company's most advanced asset is ontunisertib (AGMB-129), an oral, gut-restricted ALK5 inhibitor for Fibrostenosing Crohn's Disease (FSCD). FSCD is a severe complication of Crohn's where intestinal inflammation leads to scarring and narrowing of the intestines, often requiring repeated surgeries.

Similar to the strategy with its lung drug, ontunisertib is designed to act locally in the intestine to halt fibrosis without being absorbed into the bloodstream. In April 2026, Agomab announced positive interim results from a Phase 2a study, and it plans to start a pivotal Phase 2b trial later this year. The U.S. FDA has already granted the program Fast Track Designation, underscoring the high unmet need.

The company is also exploring another major pathway involved in tissue repair, the HGF/MET pathway, with two preclinical antibody candidates, AGMB-101 and AGMB-102. This dual-pronged attack on fibrosis—both inhibiting pro-fibrotic signals with ALK5 inhibitors and promoting tissue regeneration with MET receptor agonists—positions Agomab with a comprehensive and differentiated strategy in a challenging therapeutic area.

Navigating a Crowded and Competitive Field

Agomab enters a fiercely competitive landscape. The market for IPF treatments alone is crowded, with over 80 companies developing more than 100 novel therapies. Competitors are exploring a wide array of biological targets, from autotaxin inhibitors to SRC tyrosine kinase inhibitors, all vying to improve upon the current standard of care.

The company's success will hinge on its ability to demonstrate a superior risk-benefit profile. The organ-restricted approach is its key differentiator, a high-stakes bet that it can solve the toxicity puzzle that has stymied the development of other potent anti-fibrotic agents. The upcoming data for AGMB-447 will be the first major test of this hypothesis in the pulmonary space. As Agomab's management team prepares for its multi-conference tour, all eyes will be on whether their precision-based approach can deliver the breakthrough that patients with fibro-inflammatory diseases have been waiting for. The journey from a promising preclinical concept to a marketable therapy is long and fraught with risk, but the upcoming clinical milestones will be critical in determining the company's trajectory.